Mechanisms Involved in the Adverse Cardiovascular Effects of Selective Cyclooxygenase-2 Inhibitors
Authors:
- Oscar Jesus Leal-RamosOLOscar Jesus Leal-Ramos
- Luis Felipe Arias-RuizLALuis Felipe Arias-Ruiz
- José Miguel Huerta-VelázquezJHJosé Miguel Huerta-Velázquez
- José Pablo Lamoreaux-AguayoJLJosé Pablo Lamoreaux-Aguayo
- Dalton ButcherDBDalton Butcher
- Asela Berenice López-CuellarALAsela Berenice López-Cuellar
- Karina Iveth Orozco-JiménezKOKarina Iveth Orozco-Jiménez
- Olivia Torres-BugarínOTOlivia Torres-Bugarín
Open Access
- 28 November 2025
- journal article
- review article
- Published by MDPI AG in Cardiovascular Medicine
- Vol. 28 (1) , 5
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for managing inflammation, but they are associated with gastrointestinal and renal toxicity upon long-term use. Selective cyclooxygenase-2 (COX-2) inhibitors, or coxibs, were developed to avoid these adverse effects while maintaining anti-inflammatory efficacy. However, accumulating evidence indicates that coxibs may increase the risk of cardiovascular complications. This review explores the pathophysiological mechanisms underlying adverse cardiovascular effects in patients treated with COX-2 inhibitors. These mechanisms include an imbalance between prothrombotic and antithrombotic factors, an altered endocannabinoid metabolism, and downregulation of PPARδ, contributing to thrombosis. Additionally, COX-2 inhibition disrupts renal prostaglandin synthesis, particularly PGE2 and prostacyclins, reduces EP4 receptor expression in macrophages, promotes chemotaxis, and elevates arterial pressure via increased iNOS, ADMA, and L-NMMA activity. At the molecular level, genetic polymorphisms, matrix metalloproteinases, signaling cross-talk, and direct cardiomyocyte injury are implicated. Collectively, these alterations promote a prothrombotic state, fluid retention, enhanced vasoconstriction, impaired vasodilation, myocardial injury, cell death, and cardiac fibrosis. Despite these risks, coxibs are often prescribed without adequate cardiovascular assessment, particularly in patients with pre-existing cardiovascular risk factors. Greater awareness of these mechanisms is essential to optimize the benefit–risk ratio in clinical decision-making involving selective COX-2 inhibitors.Keywords
This publication has 50 references indexed in Scilit:
- OsteoarthritisMedical Clinics of North America, 2020
- Early Diagnosis and Treatment of Rheumatoid ArthritisPrimary Care: Clinics in Office Practice, 2018
- Cardiovascular Concerns in BRCA1 and BRCA2 Mutation CarriersCurrent Treatment Options in Cardiovascular Medicine, 2018
- Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: Immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2Chemico-Biological Interactions, 2017
- Nonsteroidal anti-inflammatory drugs for dysmenorrhoeaCochrane Database of Systematic Reviews, 2015
- Genetic Polymorphisms and the Cardiovascular Risk of Non-Steroidal Anti-Inflammatory DrugsThe American Journal of Cardiology, 2010
- Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: Implication for the adverse effects of cyclooxygenase-2 inhibitorsClinical Pharmacology & Therapeutics, 2006
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Effects of Celecoxib and Naproxen on Renal Function in the ElderlyArchives of internal medicine (1960), 2000
- Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase -2–selective inhibitionThe American Journal of Medicine, 1999